Cardiol Therapeutics (CRDL) Common Equity (2020 - 2026)

Cardiol Therapeutics has reported Common Equity for 7 years, with the latest figure at -$163.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 24.91% year-over-year to -$163.3 million; the trailing twelve-month figure through Mar 2026 stood at -$163.3 million (down 24.91% YoY), and the FY2025 full-year result was -$152.8 million, down 219.02% from the prior year.
• Common Equity for Q1 2026 stood at -$163.3 million, down from -$152.8 million in the prior quarter.
• The five-year high for Common Equity was $149.6 million in Q3 2025, with the low at -$163.3 million in Q1 2026.
• Historically, Common Equity has averaged -$1.0 million across 5 years, with a median of $29.6 million in 2022.
• Annual changes were most pronounced in 2024 — Common Equity soared 518.74% — and 2025, when it sank 219.02%.
• Cardiol Therapeutics' Common Equity stood at $38.5 million in 2022, then sank by 46.05% to $20.7 million in 2023, then soared by 518.74% to $128.4 million in 2024, then slumped by 219.02% to -$152.8 million in 2025, then slipped by 6.85% to -$163.3 million in 2026.
• The last three Common Equity figures came in at -$163.3 million (Q1 2026), -$152.8 million (Q4 2025), and $149.6 million (Q3 2025), per Business Quant data.